Many clinical drugs have been invented to treat or manage T2DM by (a) stimulating the secretion of insulin and (b) interrupting or delaying the digestion of dietary starch to reduce the rate of blood sugar absorption from the small intestine [25]. The gene discussed is INS; the disease is type 2 diabetes mellitus.